GSK in talks to buy cancer biotech Nuvalent for more than $9bn

GSK is in discussions to acquire cancer biotech Nuvalent for over $9 billion, a move that would represent one of the UK drugmaker's most significant acquisitions. The potential deal comes as merger and acquisition activity within the biotechnology sector accelerates in 2024. Nuvalent focuses on developing targeted therapies for patients with difficult-to-treat cancers, particularly those with specific genetic mutations. The company's lead drug candidates, NV300 and NV515, are in clinical trials for non-small cell lung cancer and other solid tumors. A successful acquisition by GSK would bolster its oncology pipeline, a key area of focus for the pharmaceutical giant. This potential transaction highlights a renewed interest from large pharmaceutical companies in acquiring innovative biotech firms to drive growth and expand their portfolios in specialized therapeutic areas. The valuation of over $9 billion underscores the significant premium being placed on companies with promising late-stage drug candidates and strong intellectual property in the competitive oncology market.